Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
This article was originally published in Scrip
Executive Summary
Long-time stem cell standard-bearer Geron and Canadian speciality pharma firm Angiotech Pharmaceuticals are both pulling out of stem cell therapy citing funding problems, but the Australia company Mesoblast, a relative newcomer to the field is still pursuing its cellular therapy ambitions.